Speaker

Dr. Xuetao Cao is the President of the Nankai University and the Director of Center for Immunotherapy, Chinese Academy of Medical Sciences (CAMS), China. He has been Professor and Director of China’s National Key Laboratory of Medical Immunology since 2006 and was elected to the Chinese Academy of Engineering in 2005, German Academy of Sciences in 2013, US National Academy of Medicine in 2016, American Academy of Arts and Sciences in 2017. He is also the Secretary General of the Federation of Immunological Societies of Asia-Oceania (FIMSA) and the President of Chinese Society of Biomedical Engineering.

His major research interests include innate immunity and inflammation, cancer immunotherapy. His group has independently identified 22 novel molecules from human dendritic cell (DC), also identified a new regulatory DC subset. His group has been heading Phase III clinical trial of DC-based cancer chemoimmunotherapy. Recently his group identified important sensors and regulators of DC/macrophages-mediated antiviral innate immune response. As corresponding author, he published more than 270 original papers in peer-reviewed journals.

曹雪涛，中国工程院院士，美国国家医学科学院院士，德国科学院院士。现为南开大学校长，研究生院院长，亚洲—大洋洲免疫学会联合会（FIMSA）秘书长和中国生物医学工程学会会长。主要研究方向包括先天免疫和炎症，癌症免疫疗法。其课题组已从人类树突状细胞（DC）中独立鉴定出22种新分子，鉴定了新的调控DC子集，领导基于DC的癌症化学免疫疗法的III期临床试验并确定了DC /巨噬细胞介导的抗病毒先天免疫应答的重要传感器和调节剂。作为通讯作者，他在同行评审期刊上发表了270余篇原创论文。

« Go Back